Support Centre
26 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Effectiveness of assertive community treatment versus care-as-usual for patients with severe and persistent psychiatric disorders
DOI 10.1186/ISRCTN11281756
ClinicalTrials.gov identifier
EudraCT number
Public title Effectiveness of assertive community treatment versus care-as-usual for patients with severe and persistent psychiatric disorders
Scientific title
Acronym N/A
Serial number at source NTR281; ZonMw: 100-103-016
Study hypothesis Assertive community treatment (ACT) will, compared to care-as-usual, result in less admission days and more sustained contact with mental health. Moreover, life skills will be more improved possibly resulting in a higher quality of life.
Lay summary
Ethics approval Received from the local medical ethics committee
Study design Randomised, active controlled, parallel group trial
Countries of recruitment Netherlands
Disease/condition/study domain Psychiatric, mental disorders/illness
Participants - inclusion criteria Mental health patients with a Health of the Nation Scales (HoNOS) total score above 14
Participants - exclusion criteria Does not comply with the above inclusion criteria
Anticipated start date 01/09/2004
Anticipated end date 31/08/2006
Status of trial Completed
Patient information material
Target number of participants 100
Interventions Assertive community treatment (ACT): in ACT the case load is a shared responsibility for the whole team. ACT is further characterised by:
1. A low staff-to-patient ratio (1 - 10 maximum)
2. In vivo treatment at home of the patient
3. The inclusion of a wide range of disciplines in the ACT team, including client participation

Fidelity is measured by 28 items.
Primary outcome measure(s) 1. Admissions/admission days
2. Care consumption
3. Sustained contact with mental health
4. Life skills
Secondary outcome measure(s) 1. Psychiatric symptoms
2. Quality of life
3. Satisfaction with care
4. Family burden
Sources of funding The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)
Trial website
Publications 2007 results on http://www.ncbi.nlm.nih.gov/pubmed/17650271
Contact name Dr  J.W.  Bloemers
  Address GGZ,
P.O. Box 286
  City/town Winschoten
  Zip/Postcode 9670 AG
  Country Netherlands
Sponsor University Medical Centre Groningen (UMCG) (Netherlands)
  Address Department of General Practice
Hanzeplein 1
  City/town Groningen
  Zip/Postcode 9713 GZ
  Country Netherlands
  Tel +31 (0)50 361 6161
  Sponsor website: http://www.umcg.nl/azg/nl/
Date applied 20/12/2005
Last edited 03/07/2009
Date ISRCTN assigned 20/12/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.